Health Care Equipment & Services

Elevra Lithium’s May 2026 divestiture of its Ghana stake and $400 M multi‑instrument capital raise propel the company toward North American lithium expansion, focusing on high‑grade projects and U.S. incentives.

EssilorLuxottica’s steady share‑price rise, luxury‑brand moves and tech‑driven pricing strategy reshape vision‑care economics, offering investors and patients new growth and value.

Dexcom’s board moves to trust‑based ownership of shares boost governance and investor confidence, aligning with biotech best practices and market dynamics.

Humm Group’s board overhaul, litigation settlement and new securities policy boost governance, reduce risk and lower capital costs, positioning the company for growth in digital health and value‑based reimbursement.

Edwards Lifesciences sharpens its balance sheet, secures $120 M convertible debt for a low‑cost polymer mitral valve, and shows disciplined equity activity—boosting financial health while targeting LMI markets.

Insider sales and option exercises at ResMed reveal a balance of liquidity and confidence, while modest institutional holdings underline the company’s steady long‑term growth outlook.

Abbott Laboratories’ dividend yield tops 3 %, sparking a price dip but boosting Schwab’s U.S. Dividend Equity ETF, highlighting the appeal of dividend‑heavy healthcare stocks for income seekers.

Siemens Healthineers’ stock sees a moderated Goldman Sachs target yet still promises upside, as the company leverages digital health growth amid volatile markets.

Explore Steris plc’s May 11 earnings outlook—forecasting modest EPS growth, regulatory risks, and new digital service opportunities to boost margins.

Revised Morgan Stanley outlook on CVS Health: stronger pharmacy sales, cost‑control, and stable retail lift earnings, reducing near‑term risk and boosting investor confidence.